Synovial sarcoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
== Medical Therapy == | == Medical Therapy == | ||
*Conventional [[chemotherapy]], (for example, [[Doxorubicin hydrochloride]] and [[Ifosfamide]]), to reduce the number of remaining microscopic cancer cells. The benefit of chemotherapy in synovial sarcoma to overall survival remains unclear, although a recent study has shown that survival of patients with advanced, poorly differentiated disease marginally improves with doxorubicin/ifosfamide treatment. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 14:48, 10 September 2012
|
Synovial sarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Synovial sarcoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Synovial sarcoma medical therapy |
|
Risk calculators and risk factors for Synovial sarcoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
- Conventional chemotherapy, (for example, Doxorubicin hydrochloride and Ifosfamide), to reduce the number of remaining microscopic cancer cells. The benefit of chemotherapy in synovial sarcoma to overall survival remains unclear, although a recent study has shown that survival of patients with advanced, poorly differentiated disease marginally improves with doxorubicin/ifosfamide treatment.